[Clinical application of calcimimetics].
Calcimimetic agents modulate the activity of calcium-sensing receptor on the surface of parathyroid cell and suppress the secretion of parathyroid hormone. Several clinical trials demonstrated that the second-generation calcimimetics cinacalcet HCl reduced PTH level, as well as Ca x P product in secondary hyperparathyroidism, while the agents reduced PTH and calcium level in primary hyperparathyroidism.
Nishi
Hiroshi
H
Division of Nephrology and Dialysis Center, Kobe University School of Medicine.
Fukagawa
Masafumi
M
D002118:Calcium / Q000097:blood; D000069449:Cinacalcet; D002986:Clinical Trials as Topic; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000188:drug therapy*; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use*; D010280:Parathyroid Glands / Q000378:metabolism; D010281:Parathyroid Hormone / Q000097:blood / Q000378:metabolism; D010758:Phosphorus / Q000097:blood; D017410:Practice Guidelines as Topic; D044169:Receptors, Calcium-Sensing / Q000819:agonists*
D009281:Naphthalenes; D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D010758:Phosphorus; D002118:Calcium; D000069449:Cinacalcet